Canada’s Drug Agency (CDA-AMC) recommends that Spevigo should be reimbursed by public drug plans for the treatment of generalized pustular psoriasis (GPP) in adults and pediatric patients aged 12 years and older and weighing at least 40 kg if certain conditions are met.
